Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Masataka Kuwana & Arata Azuma. (2020) Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Modern Rheumatology 30:2, pages 225-231.
Read now
Read now
Cuicui Cong, Lijun Mao, Yanlin Zhang, Zanmei Zhao, Xixian Xu & Jinyuan Zhao. (2014) Regulation of silicosis formation by lysophosphatidic acid and its receptors. Experimental Lung Research 40:7, pages 317-326.
Read now
Read now
Eva Baroke, Jack Gauldie & Martin Kolb. (2013) New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Expert Review of Respiratory Medicine 7:5, pages 465-478.
Read now
Read now
Sabina A Antoniu. (2008) Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Expert Opinion on Therapeutic Targets 12:9, pages 1077-1084.
Read now
Read now
Sabina A Antoniu. (2008) Somatostatin analogs for idiopathic pulmonary fibrosis therapy. Expert Opinion on Investigational Drugs 17:7, pages 1137-1140.
Read now
Read now
Sabina A Antoniu. (2008) Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs 17:4, pages 611-614.
Read now
Read now
Joseph P Lynch$suffix/text()$suffix/text(), Michael C Fishbein, Rajeev Saggar, David A Zisman & John A Belperio. (2007) Idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 1:3, pages 377-389.
Read now
Read now
Mehrnaz Gharaee-Kermani, Biao Hu, Victor J Thannickal, Sem H Phan & Margaret R Gyetko. (2007) Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs 12:4, pages 627-646.
Read now
Read now
Sabina A Antoniu. (2006) Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs 15:7, pages 823-828.
Read now
Read now
Victor J Thannickal, Kevin R Flaherty, Robert C Hyzy & Joseph P Lynch$suffix/text()$suffix/text(). (2005) Emerging drugs for idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs 10:4, pages 707-727.
Read now
Read now
Sabina A Antoniu. (2005) Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert Opinion on Investigational Drugs 14:11, pages 1443-1447.
Read now
Read now
Articles from other publishers (24)
Muttanagouda Giriyappagoudar, Basavaraj Vastrad, Rajeshwari Horakeri & Chanabasayya Vastrad. (2023) Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis. Biomedicines 11:12, pages 3109.
Crossref
Crossref
Yang Miao, Yanhua Wang, Zhun Bi, Kai Huang, Jingjing Gao, Xiaohe Li, Shimeng Li, Luqing Wei, Honggang Zhou & Cheng Yang. (2023) Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine 23:1.
Crossref
Crossref
Lee E Morrow, Daniel Hilleman & Mark A Malesker. (2022) Management of patients with fibrosing interstitial lung diseases. American Journal of Health-System Pharmacy 79:3, pages 129-139.
Crossref
Crossref
Xiaohe Li, Kai Huang, Xiaowei Liu, Hao Ruan, Ling Ma, Jingjing Liang, Yunyao Cui, Yanhua Wang, Shuyang Wu, Hailong Li, Yuli Wei, Zeping Li, Jingjing Gao, Bo Yang, Xiaoping Li, Guang Yang, Honggang Zhou & Cheng Yang. (2021) Ellagic Acid Attenuates BLM-Induced Pulmonary Fibrosis via Inhibiting Wnt Signaling Pathway. Frontiers in Pharmacology 12.
Crossref
Crossref
Rafael Franco, Rafael Rivas-Santisteban, Joan Serrano-Marín, Ana I. Rodríguez-Pérez, José L. Labandeira-García & Gemma Navarro. (2020) SARS-CoV-2 as a Factor to Disbalance the Renin–Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production. The Journal of Immunology 205:5, pages 1198-1206.
Crossref
Crossref
Hui Jia, Zuo-jun Wang, Qiong Wu, Zi-ru Xu, Jing-yi Zhang, Hong-da Ma & Qing-chun Zhao. (2018) Antifibrosis effects of Shenge Yangfei Capsules on bleomycin-induced pulmonary fibrosis in rats. Chinese Herbal Medicines 10:4, pages 411-415.
Crossref
Crossref
Chaoming Zhou, Fang Liu, Phillip H. Gallo, Mark E. Baratz, Sandeep Kathju & Latha Satish. (2016) Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Sunad Rangarajan, Morgan L. Locy, Tracy R. Luckhardt & Victor J. Thannickal. (2016) Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?. Drugs 76:3, pages 291-300.
Crossref
Crossref
Rana Herro & Michael Croft. (2016) The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF Superfamily member 14). Pharmacological Research 104, pages 151-155.
Crossref
Crossref
Dalia I. Ismail & Eman A. Farag. (2015) Propolis protects against bleomycin-induced pulmonary fibrosis through mitochondrial-dependent pathway. The Egyptian Journal of Histology 38:4, pages 732-741.
Crossref
Crossref
Azhar A. Supariwala, Horiana Grosu & Raymonde E. Jean. (2012) Severe Lenalidomide-induced Interstitial Pneumonitis Requiring Mechanical Ventilation. Clinical Pulmonary Medicine 19:3, pages 113-118.
Crossref
Crossref
Eva Baroke, Shyam Maharaj & Martin Kolb. (2011) Clinical trials in idiopathic pulmonary fibrosis: update and perspectives. Clinical Investigation 1:12, pages 1669-1680.
Crossref
Crossref
Kevin O'Brien, James Troendle, Bernadette R. Gochuico, Thomas C. Markello, Jose Salas, Hilda Cardona, Jianhua Yao, Isa Bernardini, Richard Hess & William A. Gahl. (2011) Pirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis. Molecular Genetics and Metabolism 103:2, pages 128-134.
Crossref
Crossref
Jian Gao, Yan Huang, Ping Li, Dujuan Xu, Jun Li, Yong Liu, Zhaogang Huang, Qiang Wu & Xu Shao. (2011) Antifibrosis effects of total glucosides of Danggui–Buxue–Tang in a rat model of bleomycin-induced pulmonary fibrosis. Journal of Ethnopharmacology 136:1, pages 21-26.
Crossref
Crossref
Ganesh Raghu, Harold R. Collard, Jim J. Egan, Fernando J. Martinez, Juergen Behr, Kevin K. Brown, Thomas V. Colby, Jean-François Cordier, Kevin R. Flaherty, Joseph A. Lasky, David A. Lynch, Jay H. Ryu, Jeffrey J. Swigris, Athol U. Wells, Julio Ancochea, Demosthenes Bouros, Carlos Carvalho, Ulrich Costabel, Masahito Ebina, David M. Hansell, Takeshi Johkoh, Dong Soon Kim, Talmadge E. KingJr.Jr., Yasuhiro Kondoh, Jeffrey Myers, Nestor L. Müller, Andrew G. Nicholson, Luca Richeldi, Moisés Selman, Rosalind F. Dudden, Barbara S. Griss, Shandra L. Protzko & Holger J. Schünemann. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine 183:6, pages 788-824.
Crossref
Crossref
Monica R. SmithSrinivasa R. GangireddyVenkata R. NaralaCory M. Hogaboam, Theodore J. StandifordPaul J. Christensen, Anand K. Kondapi & Raju C. Reddy. (2010) Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology 298:5, pages L616-L625.
Crossref
Crossref
Brent W. Kinder, Cyrus Shariat, Harold R. Collard, Laura L. Koth, Paul J. Wolters, Jeffrey A. Golden, Ralph J. Panos & Talmadge E. KingJr.Jr.. (2010) Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function. Lung 188:2, pages 143-149.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2009. Annual Reports in Medicinal Chemistry Volume 44. Annual Reports in Medicinal Chemistry Volume 44
577
632
.
Jami E. Milam, Venkateshwar G. Keshamouni, Sem H. Phan, Biao Hu, Srinivasa R. Gangireddy, Cory M. Hogaboam, Theodore J. Standiford, Victor J. Thannickal & Raju C. Reddy. (2008) PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology 294:5, pages L891-L901.
Crossref
Crossref
Shaojun Shi, Jianhong Wu, Huating Chen, Hui Chen, Jun Wu & Fandian Zeng. (2007) Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers. The Journal of Clinical Pharmacology 47:10, pages 1268-1276.
Crossref
Crossref
Keiji Kuba, Yumiko Imai, Shuan Rao, Chengyu Jiang & Josef M. Penninger. (2006) Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. Journal of Molecular Medicine 84:10, pages 814-820.
Crossref
Crossref
Jeffrey J. Swigris & Kevin K. Brown. (2006) Fibrose pulmonar idiopática: uma década de progressos. Jornal Brasileiro de Pneumologia 32:3, pages 249-260.
Crossref
Crossref
F.J. Martinez, C.M. Hogaboam, E.S. Choi, G.B. Toews, K.R. Flaherty & V.J. Thannickal. 2006. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
440
448
.
Anuk M. Das, Don E. Griswold, Christopher J. Molloy, Andrew A. Protter & Geoffrey J. Laurent. (2004) Fighting pulmonary fibrosis: new science brings new therapeutic opportunities. Drug Discovery Today: Therapeutic Strategies 1:3, pages 361-368.
Crossref
Crossref